170 related articles for article (PubMed ID: 38654944)
1. Visceral Leishmaniasis (VL) Clinical Presentation, Laboratory Findings, Treatment Options and Outcome.
Khodabandeh M; Moradian E; Sarvari M; Khiabani MS
Iran J Parasitol; 2024; 19(1):28-37. PubMed ID: 38654944
[TBL] [Abstract][Full Text] [Related]
2. Visceral Leishmaniasis in Southwestern Iran: A Retrospective Clinico-Hematological Analysis of 380 Consecutive Hospitalized Cases (1999-2014).
Sarkari B; Naraki T; Ghatee MA; Abdolahi Khabisi S; Davami MH
PLoS One; 2016; 11(3):e0150406. PubMed ID: 26942443
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological and clinical features of visceral leishmaniasis in children in Alicante Province, Spain.
Ramos JM; Clavijo A; Moral L; Gavilan C; Salvador T; González de Dios J
Paediatr Int Child Health; 2018 Aug; 38(3):203-208. PubMed ID: 29790825
[TBL] [Abstract][Full Text] [Related]
4. Clinical Features and Laboratory Findings of Visceral Leishmaniasis in Children Referred To Children Medical Center Hospital, Tehran, Iran during 2004-2011.
Tofighi Naeem A; Mahmoudi S; Saboui F; Hajjaran H; Pourakbari B; Mohebali M; Zarkesh MR; Mamishi S
Iran J Parasitol; 2014 Mar; 9(1):1-5. PubMed ID: 25642253
[TBL] [Abstract][Full Text] [Related]
5. Identification of
Alabaz D; Eroğlu F; Elçi H; Çay Ü
Mediterr J Hematol Infect Dis; 2022; 14(1):e2022053. PubMed ID: 35865400
[TBL] [Abstract][Full Text] [Related]
6. Pediatric visceral leishmaniasis in northwest of Iran.
Abdinia B; Oliaei-Motlagh M; Teimouri-Dereshki A
Medicine (Baltimore); 2016 Nov; 95(44):e5261. PubMed ID: 27858891
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Laboratory Findings of Visceral Leishmaniasis in Children Hospitalized in Mashhad, Northeastern Iran: A Twenty-Year Retrospective Study.
Shamsian SA; Fata A; Alinezhad R; Mohebali M; Sadabadi F; Moghaddas E; Fakhar M
Iran J Parasitol; 2020; 15(4):495-499. PubMed ID: 33884006
[TBL] [Abstract][Full Text] [Related]
8. Leishmaniasis in Sudan. Visceral leishmaniasis.
Zijlstra EE; el-Hassan AM
Trans R Soc Trop Med Hyg; 2001 Apr; 95 Suppl 1():S27-58. PubMed ID: 11370250
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Four Adult Visceral Leishmaniasis Cases.
Çabalak M; Çulha G; Kaya T; Gürsoy D; İlhan G; Özbilgin A
Turkiye Parazitol Derg; 2023 Dec; 47(4):275-279. PubMed ID: 38149450
[No Abstract] [Full Text] [Related]
11. [An adult case of visceral leishmaniasis in a province of Black-Sea region, Turkey].
Oztoprak N; Aydemir H; Pişkin N; Seremet Keskin A; Araslı M; Gökmen A; Celebi G; Külekçi Uğur A; Taylan Özkan A
Mikrobiyol Bul; 2010 Oct; 44(4):671-7. PubMed ID: 21063981
[TBL] [Abstract][Full Text] [Related]
12. A 10-Year Retrospective Study on Pediatric Visceral Leishmaniasis in a European Endemic Area: Diagnostic and Short-Course Therapeutic Strategies.
Dondi A; Manieri E; Gambuti G; Varani S; Campoli C; Zama D; Pierantoni L; Baldazzi M; Prete A; Attard L; Lanari M; Melchionda F
Healthcare (Basel); 2023 Dec; 12(1):. PubMed ID: 38200929
[TBL] [Abstract][Full Text] [Related]
13. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Lima MA; Mitra G; Verma N; Balasegaram M; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2603. PubMed ID: 24392168
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological features of visceral leishmaniasis in fars province, southern iran.
Sarkari B; Hatam G; Ghatee M
Iran J Public Health; 2012; 41(4):94-9. PubMed ID: 23113170
[TBL] [Abstract][Full Text] [Related]
16. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
[TBL] [Abstract][Full Text] [Related]
17. Current clinical, laboratory, and treatment outcome characteristics of visceral leishmaniasis: results from a seven-year retrospective study in Greece.
Georgiadou SP; Stefos A; Spanakos G; Skrimpas S; Makaritsis K; Sipsas NV; Dalekos GN
Int J Infect Dis; 2015 May; 34():46-50. PubMed ID: 25743761
[TBL] [Abstract][Full Text] [Related]
18. Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics.
Scarpini S; Dondi A; Totaro C; Biagi C; Melchionda F; Zama D; Pierantoni L; Gennari M; Campagna C; Prete A; Lanari M
Microorganisms; 2022 Sep; 10(10):. PubMed ID: 36296164
[TBL] [Abstract][Full Text] [Related]
19. Demographic Characteristics besides Clinical and Laboratory Manifestations of Children with Visceral Leishmaniasis in Rasht, Northern Iran.
Hashemian H; Baghersalimi A; Asgharzadeh M; Mahdipour M
Iran J Parasitol; 2023; 18(2):229-236. PubMed ID: 37583640
[TBL] [Abstract][Full Text] [Related]
20. Visceral leishmaniasis from a non-endemic Himalayan region of Nepal.
Shrestha M; Pandey BD; Maharjan J; Dumre SP; Tiwari PN; Manandhar KD; Pun SB; Pandey K
Parasitol Res; 2018 Jul; 117(7):2323-2326. PubMed ID: 29717371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
